{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 215,
  "pageCount": 366,
  "prevPage": 214,
  "nextPage": 216,
  "slideType": "preempt_rebuttal",
  "function": "expose_contradiction",
  "density": "sparse",
  "nDataPoints": 0,
  "notes": "The slide functions as a 'fraud-exposure' or 'villain-critique' framework, systematically dismantling the credibility of the clinical trial data.",
  "elementsJson": [
    "paragraph",
    "numbered_list"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/215",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-215",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The pages ahead will highlight red flags, statistical tricks, and omissions in the principal trials upon which FDA approval was based – HARMONY 1, 1-bis, CTP, and 3.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d1-73a9-abb7-bea9db52912f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.68,
        "w": 0.86,
        "x": 0.07,
        "y": 0.24
      },
      "kind": "list",
      "text": "1. Only 'successful' trials are presented... 2. Published papers for trials are missing... 3. Trials are conducted in low-quality geographies... 4. Unreasonably short trial and timelines... 5. Cherry-picked trial intervals... 6. Fuzzy inclusion criteria... 7. Trials excluded patients with comorbidities... 8. Low quality primary endpoint using ESS.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "352dacf8-e90e-4a98-853f-eb6573578238",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "The pages ahead will highlight red flags, statistical tricks, and omissions in the principal trials upon which FDA approval was based – HARMONY 1, 1-bis, CTP, and 3. We discuss each trial one by one, but first we summarize the modus operandi and problems common to the pitolisant clinical trials.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1531b60b-bfc1-42bc-9c38-b3de13c87f51",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "c6221f8f-4d4b-4495-91ad-c6c8939da11c",
      "evidence": "Systematic listing of methodological flaws and data manipulation allegations.",
      "confidence": 0.95
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}